Optimer Pharmaceuticals Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: San Diego CA United States (1998)
Status: Acquired by Cubist (2013) → now Merck (2014)

Organization Overview

First Clinical Trial
2004
NCT00097422
First Marketed Drug
2011
fidaxomicin (dificid)
First NDA Approval
2011
fidaxomicin (dificid)
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Optimer Pharmaceuticals, Inc. | Optimer Pharmaceuticals LLC

Active Ingredients

Marketed Drugs (1)

fidaxomicin (dificid) (2011 NDA)

Drugs in Phase 4 Trials (2)

fidaxomicin (dificid) (6 trials)

vancomycin (Vancocin) (3 trials)

Drugs in Phase 3 Trials (1)

prulifloxacin (1 trial)

Indications

Approved Indications


 

Diarrhea

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 4)

Communicable Diseases (Phase 4)

Diarrhea (Phase 3)

Gastroenteritis (Phase 3)

Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 3